Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer

M Basade, M Singhal, AK Rathi, M Nandi, S Minhas, C Goswami, S Shinde, PM Parikh, S Aggarwal

South Asian Journal of Cancer 2018 7(2):146-150

Metastatic breast cancer (MBC) is cancer that has spread from the breast to another part of the body or has come back in another distant location. Treatment options for MBC depend on several factors, including where the cancer has spread, the patient's overall health, and the levels of hormone receptors and HER2 in the tumour. Over-expression of HER2 is generally considered to be a negative prognostic feature because it accompanies an increase in breast cancer mortality. However, the development of agents that specifically target HER2 has improved the management of patients with these tumours.[7],[8],[9],[10] This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations in regards with the use of these agents and the management of HER2 positive MBC for the benefit of community oncologists.

https://ift.tt/2GWkeJg